PDE4 inhibitors 2001. Patent and literature activity 2000 - September 2001

Abstract

Patenting activity relating to PDE4 inhibitors remains at a sustained level, with a slight upward trend in the number of published applications. A total of 59 applications were published in 2000 and current trends suggest approximately 63 will be published in 2001. The most active companies, each accounting for 13 applications within this period are the two companies, GlaxoSmithKline and Byk Gulden, with compounds in advanced Phase III studies. Another 18 companies and institutions have published their first claims in this field during this period, most notably ICOS, with 8 applications published in June 2001. With regulatory filings for both cilomilast and roflumilast likely to be filed in 2002, interest in this area is likely to increase during the next few years.

• asthma
• COPD
• dermatitis
• leukaemia
• PDE 4 inhibitor
• rheumatoid arthritis
• TNF
• ulcerative colitis